{"id":"W4399437467","doi":"10.1007/s00417-024-06531-9","title":"Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes","year":2024,"lang":"en","type":"review","venue":"Graefe s Archive for Clinical and Experimental Ophthalmology","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche; Roche","keywords":"Aflibercept; Macular degeneration; Medicine; Ranibizumab; Ophthalmology; Pegaptanib; Bevacizumab; Choroidal neovascularization; Placental growth factor; Clinical trial; Diabetic macular edema; Diabetic retinopathy; Macular edema; Vascular endothelial growth factor; Surgery; Internal medicine; VEGF receptors; Retinal; Diabetes mellitus; Chemotherapy; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004076945,0.001073279,0.001485896,0.0005080713,0.0004396208,0.001767392,0.000895485,0.00152477,0.003933114],"category_scores_gemma":[0.001446829,0.0003326696,0.00188333,0.0004339209,0.000570924,0.00107001,0.0004909268,0.002930457,0.001010967],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001035341,"about_ca_system_score_gemma":0.001856241,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009971595,"about_ca_topic_score_gemma":0.002642044,"domain_scores_codex":[0.9993764,0.0002124687,0.00004349801,0.00006029111,0.0001360869,0.0001713673],"domain_scores_gemma":[0.9992558,0.000138855,0.0001751605,0.00006227252,0.0001389208,0.0002289658],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.08893333,0.04636567,0.004886748,0.005662459,0.002851652,0.0005878216,0.000615956,0.003300651,0.0799806,0.003038132,0.02835606,0.735421],"study_design_scores_gemma":[0.209168,0.5168657,0.03728306,0.0031645,0.004258662,0.002197255,0.0003725623,0.004732509,0.04950516,0.004895196,0.1673137,0.0002436503],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.6589287,0.3002641,0.005585277,0.005827649,0.001268131,0.006226936,0.003615765,0.0005005672,0.01778288],"genre_scores_gemma":[0.8273256,0.1313746,0.006697433,0.01155514,0.0007502153,0.00549368,0.006233228,0.000149798,0.0104204],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.004076945,"threshold_uncertainty_score":0.02156121,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2337610196381718,"score_gpt":0.5444026712076712,"score_spread":0.3106416515694993,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}